Credit Suisse Starts AC Immune SA (ACIU) at Outperform
- Wall Street falls with financials, other post-election gainers
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- United Airlines (UAL) Tops Q4 EPS by 5c
- Obama shortens sentence of Manning, who gave secrets to WikiLeaks
- After-Hours Stock Movers 01/17: (SHLO) Higher; (GIMO) (AFAM) (CSX) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Credit Suisse initiates coverage on AC Immune SA (NASDAQ: ACIU) with a Outperform rating and a price target of $18.00.
Analyst Alethia Young commented, "AC Immune is focused on neurodegenerative diseases, primarily Alzheimer’s Disease (AD). Their lead asset, crenezumab, is in Phase 3 in partnership with Roche. AC Immune is developing more than just crenezumab which allows for some optionality with early AD targets like Tau or AD vaccines. In this report, we will focus on near-term catalyst which will be a stock read-through from a competitive Phase 3 program being developed by Lilly. We view this story as high risk/high reward in the nearterm. In the long-term post the headline risk, we are positive for 3 reasons: 1) no AD asset is exactly the same and designs differ so it will be uncertain that if solanezumab (Sola) fails all drugs fail, 2) their Ph3 and Biogen's (another competitor) will continue even if Lilly is a complete fail, and 3) AC Immune has other assets that could be used in combination or separately from crenezumab."
Shares of AC Immune SA closed at $14.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Starts Bio-Rad Labs (BIO) at Hold
- Deutsche Bank Starts Thermo Fisher Scientific (TMO) at Buy
- Deutsche Bank Starts Waters Corp. (WAT) at Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Hot New Coverage, New Coverage
Related EntitiesCredit Suisse
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!